We are dedicated to discovering, developing and delivering cures for intractable and rare diseases.
We are passionate about helping patients lead more hopeful, healthier and happier lives
ASC Therapeutics is
"HERE TO CURE".
ASC Therapeutics is a fully incorporated biopharmaceutical company focusing on the development of curative therapeutic products that are enabled by our proprietary gene editing platform, TARGATT™ and other gene editing technologies developed after 12 years of R&D at Applied Stem Cells, Inc.
The company’s therapeutic development pipeline includes several preclinical stage programs in gene and cell therapy progressing into clinical stage in 2022 focusing on several blood disorders.
To provide cures to patients with intractable diseases through innovative technologies and therapeutics that are both groundbreaking and safe.
ASC Therapeutics strives to discover, develop, and deliver gene and cell treatments to cure intractable and emerging diseases.
Our diverse team has decades of experience in cutting edge stem-cell and gene therapy research. Together we strive to be innovators to provide platforms to revolutionize the way diseases are treated.
Our current pipeline is focused on blood diseases. We are devoted to discovering, developing and delivering cures for intractable diseases using gene and cell therapies.
Not only do we have experienced teams for discovery research, CMC, pre-clinical and clinical development, we also collaborate with leading academic and industry partners around the world to advance and expand our product pipeline. Building upon our deep knowledge in stem cell, gene therapy and genome editing technology, we are devoted to discovering, developing and delivering cures for intractable diseases.
NEWS & BLOG
Latest News & Blogs Posts
Hermed Capital Fund (the “Fund”) is a private equity fund that will invest primarily in healthcare industry around the world.
Fosun International Limited is a technology-driven consumer group that has been listed on the main board of the Hong Kong Stock Exchange (00656.HK) since 2007.
Ping An Group
Ping An of China is devoted to becoming a world-leading personal financial services provider.
Simcere Pharmaceutical Group is China's leading R&D-driven pharmaceutical company. It has been ranked amongst the top 100 pharmaceutical companies in China and in the top 10 of the most innovative pharmaceutical companies in China for several consecutive years. Simcere was the first Chinese biological and chemical pharmaceutical company to be listed on the New York Stock Exchange.
Launched in January 2016 by Mr. Jianming Yu, Advantech Capital is a private equity fund, focused on innovation-driven growth capital in China.
Stanford University, officially Leland Stanford Junior University, is a private research university in Stanford, California. Stanford is known for its academic achievements, wealth, close proximity to Silicon Valley, and selectivity; it ranks as one of the world's top universities.
Emory University, a top-ranked private institution recognized internationally for its outstanding liberal arts colleges, graduate and professional schools, and one of the world's leading healthcare systems, is located on a beautiful campus in Atlanta, Georgia's historic Druid Hills neighborhood.
Shantou University, a key comprehensive university under the provincial Project 211 program in Guangdong, was founded in 1981 with the approval of the State Council. It is the only public university that receives funding from the Li Ka Shing Foundation.
Peking University Shenzhen Hospital
Peking University Shenzhen Hospital, opened in 1999, is a modern general hospital based in Shenzhen with an investment of RMB 4.5 billion. Under the cooperation of Shenzhen municipal government and Peking University, the hospital was absorbed into the management system of Peking University Hospital in the year 2001.
Stem cell and gene editing platforms for research
IND enabling stage for two programs
Applied stem cell spinoff in
June 2020 Received two
FDA’s orphan drug
FDA's Fast Track Designation and
EMA's Orphan Drug Designation for ASC618